

**LISTING OF CLAIMS:**

This listing of claims provided below will replace all prior versions and listings of claims in the application.

Please amend the claims as follows:

1-21. (Canceled).

22. (Currently amended) A pharmaceutical composition comprising a therapeutically effective amount of unitary doses of viral particles of recombinant adenoviral vectors,

wherein said unitary dose is from about  $10^7$  to about  $10^{14}$  viral particles;

wherein the adenoviral vectors comprise an adenoviral genome replaced with a therapeutic gene or DNA sequence regulated by a ubiquitous promoter, a tissue-specific promoter, or a combination thereof, that encodes for one or more therapeutic proteins for the treatment of fibrotic disorders in organs;

and a pharmaceutically compatible carrier,

wherein the therapeutic proteins for the treatment of fibrotic disorders are selected from the group consisting of ~~+(i)~~ a latent or active protein selected from the group consisting of matrix metalloprotease-8 ("MMP-8"), matrix metalloprotease-1, matrix metalloprotease-2, matrix metalloprotease-9, matrix metalloprotease-13 and combinations thereof; ~~(ii)~~ and the truncated receptor for transforming growth factor- $\beta$  ("TGF- $\beta$ ") type II;

~~—— (iii) ——~~ hepatocyte growth factor ("HGF");

~~—— (iv) ——~~ betaglycan; and ~~——~~

~~—— (v) ——~~ Smad-7.

23. (Canceled).

24. (Currently Amended) A method of treating fibrotic disorders in a patient, comprising:

preparing a recombinant adenoviral vector containing a therapeutic gene or DNA sequence of claim 22;

delivering the recombinant adenoviral vector by an administrative route to an organ; and

generating therapeutic proteins in the organ from the recombinant adenoviral vector to treat the fibrotic disorders.

25. (Previously Presented) The method of claim 24, wherein the administrative route is intravenous.

26. (Previously Presented) The method of claim 24, wherein the organ is selected from liver, lung, heart, kidney, skin, hypertrophic scars, and combinations thereof.

27. (Previously Presented) The method of claim 24, wherein the fibrotic disorders are hepatic fibrosis, pulmonary fibrosis, renal fibrosis, heart fibrosis, keloids, hypertrophic scars, or combinations thereof.

28. (Previously Presented) The pharmaceutical composition according to claim 22, wherein the therapeutic protein for the treatment of fibrotic disorders is MMP-8.

29. (Previously Presented) The pharmaceutical composition according to claim 22, wherein the therapeutic protein for the treatment of fibrotic disorders is MMP-1.

30. (Previously Presented) The pharmaceutical composition according to claim 29,

wherein the therapeutic protein for the treatment of fibrotic disorders is the truncated receptor for TGF- $\beta$  type II.

31. (Canceled).

32. (Currently Amended) The pharmaceutical composition according to claim 22, wherein the therapeutic protein for the treatment of fibrotic disorders is HGF matrix metalloprotease-2.

Please add the following new claims:

33. (New) The pharmaceutical composition according to claim 22, wherein the therapeutic protein for the treatment of fibrotic disorders is matrix metalloprotease-9.

34. (New) The pharmaceutical composition according to claim 22, wherein the therapeutic protein for the treatment of fibrotic disorders is matrix metalloprotease-13.